帕丘利酒精在治疗IBS-D时的机制基于BMP-Smad通路
Yu-Lin Lu1, Chen Huang1, Shu-Yan Huang1
1Research Centre of Basic Intergrative Medicine, School of Basic Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China.
概括
帕丘利酒精 (PA) 通过调节BMP-SMAD信号通路,改善了刺激性肠综合征与腹 (IBS-D) 的老鼠的胃肠功能. 这种治疗增强神经同源度,降低内脏敏感性,为IBS-D疗法提供了潜力.
科学领域:
- 胃肠病学 胃肠病学
- 神经胃肠病学 神经胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 刺激性肠综合征与腹 (IBS-D) 是一种普遍存在的功能性胃肠疾病.
- 肠道神经系统 (ENS) 和BMP-SMAD信号通路对于肠道运动和功能至关重要.
- 帕丘利酒精 (PA) 通过这种途径改善IBS-D症状的确切机制尚不清楚.
研究的目的:
- 在大鼠模型中研究帕丘利酒精 (PA) 对腹性易怒肠综合征 (IBS-D) 的治疗作用.
- 阐明潜在的神经生物学机制,特别关注BMP-SMAD信号通路.
主要方法:
- 在体内和体外的研究使用IBS-D大鼠模型进行.
- 评估结肠收缩,胃肠道运动功能,腹和内脏敏感性.
- 分析了肠道神经元中BMP-SMAD通路蛋白的表达和酸化.
主要成果:
- 帕丘利酒精 (PA) 在IBS-D大鼠中使异常结肠收缩正常化.
- PA显著改善了胃肠道运动功能,减少了腹,降低了内脏敏感性.
- 治疗PA导致BMPRII+神经元子集的增加,并调节了肠道肌肠中的BMP-SMAD信号传输.
结论:
- 帕丘利酒精 (PA) 通过改善胃肠道神经同源度来证明IBS-D的治疗潜力.
- 该机制涉及BMP-SMAD信号通路的调节和增加的BMPRII+神经元.
- 这些发现支持PA作为IBS-D治疗中进一步临床研究和药物开发的候选者.
相关概念视频
01:21Drugs for Treatment of Constipation-Predominant IBS
124
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
124
01:17Drugs for Treatment of Diarrhea-Predominant IBS
131
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
131
01:17Irritable Bowel Syndrome I: Introduction
211
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
211
01:30Irritable Bowel Syndrome III: Medical and Nursing Management
130
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
130
01:29Inflammatory Bowel Disease IV: Pharmacological Management
83
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
83
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
288
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
288